We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

C:NYSECitigroup, Inc. Analysis

Data as of 2026-06-11 - not real-time

$133.38

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Citigroup’s stock is trading at $133.38, comfortably above its 20‑day (127.60), 50‑day (126.64) and 200‑day (111.94) moving averages, while the RSI sits at 60.8 and the MACD histogram is positive, signaling a bullish technical backdrop. Volume is on the rise, support sits near $119.76 and resistance near $137.12, and the 30‑day volatility of ~26% combined with a beta of 1.42 suggests the share will continue to move sharply with the market. On the fundamentals side, revenue grew 16% YoY to $78.7 B, operating margin is a healthy 34% and forward EPS of 12.53 points to a forward P/E of 10.6, well below the industry average of 16.5, indicating the stock is undervalued. However, operating cash flow is negative (-$30.8 B) and free cash flow is flat, raising questions about the sustainability of the 1.8% dividend despite a modest payout ratio of 29%.
Recent news adds momentum: a $30 B share‑buyback announced at Investor Day, a new private‑credit partnership with BlackRock, and a strategic push into tokenized securities are drawing investor attention, while analysts collectively rate the stock as a “Buy.” The combination of bullish technicals, attractive valuation multiples, and strategic growth initiatives supports a positive near‑term outlook, though the cash‑flow weakness and heightened regulatory exposure keep risk considerations in play.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Bullish technical indicators and price above key moving averages
  • Positive catalyst from $30 B buyback and tokenization strategy
  • Undervaluation relative to industry P/E

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Strong earnings growth and improving forward EPS
  • Dividend yield provides modest income
  • Operating cash‑flow weakness and regulatory headwinds

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strategic diversification into tokenized securities and private credit
  • Sustained undervaluation with attractive forward multiples
  • Long‑term dividend and potential for continued share repurchases

Key Metrics & Analysis

Financial Health

Revenue Growth15.90%
Profit Margin20.36%
P/E Ratio16.5
ROE7.65%
ROA0.61%
P/B Ratio1.2
Op. Cash Flow$-30797000704
Industry P/E16.5

Technical Analysis

TrendBullish
RSI60.8
Support$119.76
Resistance$137.12
MA 20$127.60
MA 50$126.64
MA 200$111.94
MACDBullish
VolumeIncreasing
Fear & Greed Index84.55

Valuation

Target Price$146.93
Upside/Downside10.16%
GradeUndervalued
TypeBlend
Dividend Yield1.80%

Risk Assessment

Beta1.42
Volatility25.99%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.